8 completed. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
Follow Liver Dysfunction: new trials by email Literature Review of Liver Dysfunction trials Research Report on Liver Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function Lepodisiran - Liver Dysfunction, Healthy | Phase 1 | Completed | Eli Lilly and Company | 30 | 2025-04-23 | 2026-08-19 |
| An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage BMS-986165 - Liver Dysfunction, Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2019-02-26 | 2020-08-26 |
| An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function BMS-986231 - Liver Dysfunction, Liver Insufficiency | Phase 1 | Completed | Bristol-Myers Squibb | 76 | 2018-05-25 | 2020-08-27 |
| Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction Evogliptin - Liver Dysfunction | Phase 1 | Completed | Dong-A ST Co., Ltd. | 24 | 2016-09-22 | 2018-02-26 |
| Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function Nemonoxacin - Liver Dysfunction | Phase 1 | Completed | Zhejiang Medicine Co., Ltd. | 20 | 2016-04-14 | 2018-03-30 |
| A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function CKD-501 - Liver Dysfunction | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 26 | 2014-03-01 | 2016-07-04 |
| Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function SC Methylnaltrexone (MNTX) - Liver Dysfunction | Phase 1 | Completed | Bausch Health Americas, Inc. | 24 | 2004-03-01 | 2019-11-27 |
| Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction Irinotecan - Unspecified Adult Solid Tumor, Chemotherapy | Phase 1 | Completed | Pfizer | 2009-08-14 |
Liver Diseases (8) · Diabetes Mellitus, Type 2 (1) · Heart Failure (1) · Hepatic Insufficiency (1) · Liver Failure (1) · Neoplasms (1)
Digestive System Diseases (8) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one (1) · Irinotecan (1) · deucravacitinib (1) · lobeglitazone (1) · nemonoxacin (1)
Bristol-Myers Squibb (2) · Bausch Health Americas, Inc. (1) · Chong Kun Dang Pharmaceutical (1) · Dong-A ST Co., Ltd. (1) · Eli Lilly and Company (1) · Pfizer (1) · Zhejiang Medicine Co., Ltd. (1)
Hungary (3) · United States (3) · South Korea (2) · China (1) · Czechia (1) · Poland (1) · Slovakia (1)
Jing Zhang, Doctor (1) · Min Soo Park, Ph.D. M.D (1) · Tage Ramakrishna, MD (1)
2017 (1), 2018 (1)